TickerKhojHospitals & Diagnostics · Medical/Nursing Services · NSE: LALPATHLAB · data 2026-11-03
Dr. Lal PathLabs Limited
In plain words
Price: 5.5% below its 52-week high of ₹2,038.6.
Delivery: 63.9% of traded shares were kept for delivery over the last 10 sessions, against 56.9% over the last 60.
Latest results: a net profit of ₹170 cr for the quarter ended Jun 2026 (+28.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,891 cr |
| Net profit (last 12 months) | ₹542 cr |
| Sales growth, 3 years (yearly) | 11.1% |
| Profit growth, 3 years (yearly) | 28.3% |
At a glance
Promoters 52.9% (-0.3 pts in a year), pledged 0.0%, institutions 40.3%.
P/E 59.4, dividend yield 0.8%. Price relative to earnings and book value (low is cheaper, not better).
ROE 21.6%, ROCE 25.3%, operating margin 23.0%: how much profit it earns on the money it uses.
Debt/equity 0.08, Profit growth 28.3% and sales growth 11.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (21.6%).
- Healthy operating margin (23.0%).
- Profit grew 28.3% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
Q1 FY27
Revenue: 797.7
Net Profit: 169.5
Operating Margin: 31
EPS: 10.15
Q1 FY27
राजस्व: 797.7
नेट लाभ: 169.5
परिचालन मार्जिन: 31
EPS: 10.15
Q1 FY27
મહેસૂલ: 797.7
નેટ લાભ: 169.5
કાર્યકારી માર્જિન: 31
EPS: 10.15
Written by AI from the filed numbers and checked against them. Not a recommendation.
Smart-money activity
33/100 · Neutral over the last ~60 sessions, data 2026-11-03
- Delivery vs usual 7/30: Delivery 62.5% over the last 20 sessions vs 49.4% in the 40 before (1.27x); shares delivered per day 1.04x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 23 schemes hold it, about ₹1,737 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 46/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
16 events shown
● Dividend ● Results ● Bonus
- 30 Jul 26Dividend Dividend ₹5 (ex-date) +1.2% next session
- 24 Jul 26Results Q1 FY27 results: profit +28.0% YoY +8.3% next session
- 25 Jun 26Dividend Dividend ₹4 (ex-date) -0.8% next session
- 30 Apr 26Results Q4 FY26 results: profit −15.2% YoY +12.6% next session
- 5 Feb 26Dividend Dividend ₹3.5 (ex-date) +2.6% next session
- 30 Jan 26Results Q3 FY26 results: profit −6.4% YoY
- 19 Dec 25Bonus Bonus 1:1 (ex-date)
- 7 Nov 25Dividend Dividend ₹7 (ex-date) -0.6% next session
- 31 Oct 25Results Q2 FY26 results: profit +16.6% YoY +5.4% next session
- 6 Aug 25Dividend Dividend ₹6 (ex-date) +0.6% next session
- 31 Jul 25Results Q1 FY26 results: profit +24.4% YoY +2.5% next session
- 6 Jun 25Dividend Dividend ₹6 (ex-date) +0.6% next session
- 25 Apr 25Results Q4 FY25 results: profit +83.2% YoY +0.8% next session
- 5 Feb 25Dividend Dividend ₹6 (ex-date) -0.9% next session
- 30 Jan 25Results Q3 FY25 results: profit +18.9% YoY +3.4% next session
- 5 Nov 24Dividend Dividend ₹6 (ex-date) +0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
23 quarters shown
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹798 cr | ₹170 cr | +28.0% | 31.0% | 10.15 |
| Mar 2026 | ₹703 cr | ₹131 cr | -15.2% | 26.6% | 7.86 |
| Dec 2025 | ₹660 cr | ₹91 cr | -6.4% | 27.2% | 5.42 |
| Sept 2025 | ₹731 cr | ₹151 cr | +16.6% | 30.7% | 18.05 |
| Jun 2025 | ₹670 cr | ₹132 cr | +24.4% | 28.7% | 15.88 |
| Mar 2025 | ₹603 cr | ₹155 cr | +83.2% | 28.0% | 18.57 |
| Dec 2024 | ₹597 cr | ₹97 cr | +18.9% | 25.8% | 11.6 |
| Sept 2024 | ₹660 cr | ₹129 cr | +18.2% | 30.7% | 15.52 |
| Jun 2024 | ₹602 cr | ₹106 cr | +28.8% | 28.2% | 12.79 |
| Mar 2024 | ₹545 cr | ₹85 cr | +49.0% | 26.5% | 10.13 |
| Dec 2023 | ₹539 cr | ₹81 cr | +54.0% | 26.1% | 9.77 |
| Sept 2023 | ₹601 cr | ₹109 cr | +52.4% | 29.6% | 13.16 |
| Jun 2023 | ₹541 cr | ₹83 cr | +43.2% | 27.0% | 9.95 |
| Mar 2023 | ₹491 cr | ₹57 cr | -7.5% | 23.5% | 6.84 |
| Dec 2022 | ₹489 cr | ₹53 cr | — | 23.1% | 6.37 |
| Sept 2022 | ₹534 cr | ₹72 cr | -24.5% | 26.9% | 8.64 |
| Jun 2022 | ₹503 cr | ₹58 cr | -56.0% | 23.4% | 6.97 |
| Mar 2022 | ₹486 cr | ₹61 cr | -26.5% | 24.9% | 7.41 |
| Sept 2021 | ₹498 cr | ₹95 cr | +11.4% | 28.4% | 11.49 |
| Jun 2021 | ₹607 cr | ₹131 cr | — | 31.2% | 15.87 |
| Mar 2021 | ₹431 cr | ₹83 cr | — | 28.3% | 10.1 |
| Dec 2020 | ₹452 cr | ₹95 cr | — | 30.7% | 11.44 |
| Sept 2020 | ₹432 cr | ₹85 cr | — | 29.5% | 10.34 |
Shareholding trend
8 quarters shown
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.93% | 53.19% | 53.21% | 53.21% | 53.21% | 53.79% | 53.91% | 53.91% |
| Foreign institutions (FII) | 18.73% | 17.36% | 17.18% | 20.29% | 21.86% | 21.68% | 23.91% | 26.82% |
| Domestic institutions (DII) | 21.58% | 21.59% | 21.38% | 19.21% | 18.49% | 17.91% | 16.08% | 13.17% |
| Mutual funds | 18.68% | 18.79% | 18.62% | 16.84% | 15.90% | 15.04% | 12.84% | 10.25% |
| Retail investors | 4.00% | 4.97% | 5.20% | 4.56% | 4.07% | 4.15% | 3.98% | 3.89% |
| Number of shareholders | 1,13,559 | 1,11,037 | 1,14,527 | 1,16,167 | 1,12,703 | 1,18,656 | 1,15,699 | 1,16,236 |
Common questions
What was Dr. Lal PathLabs Limited's latest quarterly profit?
Dr. Lal PathLabs Limited reported a net profit of ₹170 cr for the quarter ended Jun 2026 (+28.0% on the same quarter a year earlier), on revenue of ₹798 cr.
How much do promoters hold in Dr. Lal PathLabs Limited?
Promoters held 52.93% of Dr. Lal PathLabs Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Dr. Lal PathLabs Limited debt-free?
Its latest reported debt-to-equity ratio is 0.08, which is very low.
What is Dr. Lal PathLabs Limited's P/E ratio?
About 59.4, based on the last 12 months' earnings and a price of ₹1,925.7 (data 2026-11-03).
What is the 52-week high and low of Dr. Lal PathLabs Limited?
The 52-week high is ₹2,038.6 and the 52-week low is ₹1,272.6.
Mutual funds holding Dr. Lal PathLabs Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 23 schemes holding about ₹1,737 cr; funds that hold it outside their top holdings may not be listed.
23 schemes shown
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.67% | ₹467 cr |
| SBI Large and Midcap Fund | SBI Mutual Fund | 0.64% | ₹259 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.17% | ₹199 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 2.30% | ₹134 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 1.63% | ₹131 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 2.03% | ₹124 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.90% | ₹101 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.62% | ₹95 cr |
| ADITYA BIRLA SUN LIFE MIDCAP FUND | Aditya Birla Sun Life Mutual Fund | 1.22% | ₹80 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 3.51% | ₹38 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.69% | ₹24 cr |
| Mirae Asset Multi Asset Allocation Fund | Mirae Asset Mutual Fund | 0.48% | ₹17 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.69% | ₹16 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.69% | ₹12 cr |
| ADITYA BIRLA SUN LIFE RETIREMENT FUND - THE 30S PLAN | Aditya Birla Sun Life Mutual Fund | 2.37% | ₹11 cr |
| Nippon India Active Momentum Fund | Nippon India Mutual Fund | 1.72% | ₹10 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.82% | ₹7 cr |
| ADITYA BIRLA SUN LIFE DIVIDEND YIELD FUND | Aditya Birla Sun Life Mutual Fund | 0.43% | ₹6 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 0.67% | ₹3 cr |
| Nippon India Nifty 500 Equal Weight Index Fund | Nippon India Mutual Fund | 0.21% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.69% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.15% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.69% | ₹0 cr |
Compared with similar companies
6 companies ranked
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Dr. Lal PathLabs Limited (this stock) | ₹1,925.7 | ₹31,681 cr | 59.4 | — | 21.6% | 25.3% | 0.08 | +22.1% |
| Dr. Agarwal's Health Care Ltd. vs LALPATHLAB → | ₹512.8 | ₹16,301 cr | 110.3 | — | 6.8% | 9.1% | 0.53 | +0.5% |
| Vijaya Diagnostic Centre Ltd. vs LALPATHLAB → | ₹1,447.1 | ₹15,014 cr | 79.6 | — | 19.7% | 19.6% | 0.44 | +46.0% |
| Metropolis Healthcare Ltd. vs LALPATHLAB → | ₹568.7 | ₹11,619 cr | 58.6 | — | 13.4% | 16.3% | 0.15 | +14.9% |
| Thyrocare Technologies Ltd vs LALPATHLAB → | ₹482.9 | ₹7,593 cr | 54 | 13.9 | 28.8% | 34.2% | 0.09 | +3.1% |
| Nephrocare Health Services Limited vs LALPATHLAB → | ₹624.6 | ₹6,274 cr | — | — | 9% | 14.6% | 0.07 | +27.5% |
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LALPATHLAB in TickerKhoj →